Swiss Rockets secured an exclusive license to MGI/Complete Genomics’ CoolMPS sequencing chemistry and plans to develop and commercialize CoolMPS‑based next‑generation sequencing (NGS) instruments outside the Asia‑Pacific region. The Basel‑based incubator announced intent to launch CoolMPS sequencers as early as next year and to rely on partners for initial manufacturing and R&D support. The deal reallocates a sequencing chemistry to a Western company and could intensify competition in NGS instrumentation, especially in Europe and the U.S. Swiss Rockets framed the move as part of a precision‑medicine strategy that pairs multiomics platforms with therapeutics development for oncology and immunology.